Peer-Reviewed Journal Details
Mandatory Fields
Cummings, E,Donohoe, G,Hargreaves, A,Moore, S,Fahey, C,Dinan, TG,McDonald, C,O'Callaghan, E,O'Neill, FA,Waddington, JL,Murphy, KC,Morris, DW,Gill, M,Corvin, A
Neuroscience Letters
Mood congruent psychotic symptoms and specific cognitive deficits in carriers of the novel schizophrenia risk variant at MIR-137
Optional Fields
Psychosis Genetics mir137 Clinical symptoms BIPOLAR DISORDER MICRORNA
Objective: The Schizophrenia Psychiatric Genome-wide Association (GWAS) Consortium recently reported on five novel schizophrenia susceptibility loci. The most significant finding mapped to a microRNA, MIR-137, which may be involved in regulating the function of other schizophrenia and bipolar disorder susceptibility genes.Method: We genotyped 821 patients with confirmed DSM-IV diagnoses of schizophrenia, bipolar affective disorder land schizoaffective disorder for the risk SNP (rs1625579) and investigated the clinical profiles of risk allele carriers using a within-case design. We also assessed neurocognitive performance in a subset of cases (n = 399) and controls (n = 171).Results: Carriers of the risk allele had lower scores for an OPCRIT-derived positive symptom factor (p = 0.04) and lower scores on a lifetime measure of psychosis incongruity (p = 0.017). Risk allele carriers also had more cognitive deficits involving episodic memory and attentional control.Conclusion: This is the first evidence that the MIR-137 risk variant may be associated with a specific subgroup of psychosis patients. Although the effect of this single SNP was not clinically relevant, investigation of the impact of carrying multiple risk SNPs in the MIR-137 regulatory network on diagnosis and illness profile may be warranted. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
DOI 10.1016/j.neulet.2012.08.065
Grant Details
Publication Themes